OB:AZT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has ArcticZymes Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AZT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.4%

AZT

-9.2%

NO Biotechs

-5.2%

NO Market


1 Year Return

1,262.2%

AZT

15.6%

NO Biotechs

-14.0%

NO Market

Return vs Industry: AZT exceeded the Norwegian Biotechs industry which returned 20.8% over the past year.

Return vs Market: AZT exceeded the Norwegian Market which returned -13.3% over the past year.


Shareholder returns

AZTIndustryMarket
7 Day1.4%-9.2%-5.2%
30 Day-8.0%5.6%-5.0%
90 Day35.9%16.5%-1.8%
1 Year1,262.2%1,262.2%15.6%15.6%-11.0%-14.0%
3 Year727.1%727.1%38.7%36.8%-3.0%-13.9%
5 Year384.2%384.2%40.2%36.0%33.6%6.9%

Price Volatility Vs. Market

How volatile is ArcticZymes Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ArcticZymes Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AZT (NOK59.8) is trading below our estimate of fair value (NOK179.47)

Significantly Below Fair Value: AZT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AZT is poor value based on its PE Ratio (59.8x) compared to the XE Biotechs industry average (33.5x).

PE vs Market: AZT is poor value based on its PE Ratio (59.8x) compared to the Norwegian market (14.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AZT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AZT is overvalued based on its PB Ratio (31.2x) compared to the NO Biotechs industry average (3.3x).


Next Steps

Future Growth

How is ArcticZymes Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ArcticZymes Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has ArcticZymes Technologies performed over the past 5 years?

42.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AZT has high quality earnings.

Growing Profit Margin: AZT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: AZT has become profitable over the past 5 years, growing earnings by 42.3% per year.

Accelerating Growth: AZT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AZT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).


Return on Equity

High ROE: AZT's Return on Equity (52.4%) is considered outstanding.


Next Steps

Financial Health

How is ArcticZymes Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: AZT's short term assets (NOK102.9M) exceed its short term liabilities (NOK10.3M).

Long Term Liabilities: AZT's short term assets (NOK102.9M) exceed its long term liabilities (NOK14.5M).


Debt to Equity History and Analysis

Debt Level: AZT is debt free.

Reducing Debt: AZT has not had any debt for past 5 years.

Debt Coverage: AZT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AZT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is ArcticZymes Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AZT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AZT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AZT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AZT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AZT's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Jethro Holter (48 yo)

1

Tenure

kr1,487,000

Compensation

Dr. Jethro Holter has been Chief Executive Officer of ArcticZymes Technologies ASA (formerly known as Biotec Pharmacon ASA) since April 22, 2020. He was an Interim CEO at Biotec Pharmacon ASA since October ...


CEO Compensation Analysis

Compensation vs Market: Jethro's total compensation ($USD156.29K) is below average for companies of similar size in the Norwegian market ($USD439.53K).

Compensation vs Earnings: Jethro's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jethro Holter
Chief Executive Officer1yrkr1.49m0.0012%
NOK 31.7k
Børge Sørvoll
Chief Financial Officer6yrskr1.33m0.053%
NOK 1.4m
Marit Lorentzen
Employee Representative Director & Director of Operations1.42yrsno data0.042%
NOK 1.1m
Alexander Bjorna
Director of IP & Business Development16.08yrsno datano data
Dino DiCamillo
Director of Marketing0.75yrno datano data

1.0yrs

Average Tenure

48yo

Average Age

Experienced Management: AZT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Marit Lorentzen
Employee Representative Director & Director of Operations1.42yrsno data0.042%
NOK 1.1m
Marie Roskrow
Chairperson2.42yrskr425.00kno data
Volker Wedershoven
Director1.42yrskr105.00k0.17%
NOK 4.5m

1.4yrs

Average Tenure

Experienced Board: AZT's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ArcticZymes Technologies ASA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ArcticZymes Technologies ASA
  • Ticker: AZT
  • Exchange: OB
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr2.707b
  • Shares outstanding: 48.33m
  • Website: https://arcticzymes.com

Number of Employees


Location

  • ArcticZymes Technologies ASA
  • Sykehusveien 23
  • PO Box 6463
  • Tromsø
  • Troms
  • 9294
  • Norway

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AZTOB (Oslo Bors)YesOrdinary SharesNONOKNov 2005
B4VDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2005
0DRVLSE (London Stock Exchange)YesOrdinary SharesGBNOKNov 2005
AZTOBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBNOKNov 2005

Biography

ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. It operates through two ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 21:53
End of Day Share Price2020/10/30 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.